Search Results

Here’s an infographic breakdown of the company’s second-quarter earnings results, including key highlights from its Innovative Medicine and MedTech businesses.

• 2025 Second-Quarter reported sales growth of 5.8% to $23.7 Billion with operational growth of 4.6%* and adjusted operational growth of 3.0%* • 2025 Second-Quarter reflects earnings per share (EPS) of $2.29 and adjusted EPS of $2.77 • Significant new product pipeline progress including approval of IMAAVY for generalized myasthenia gravis, priority review for TAR-200, data for CARVYKTI overall survival and progression-free benefits in multiple myeloma, and continuation of the clinical trial for a general surgery robotic system, OTTAVA • Strong operational performance and favorable foreign exchange results in Company increasing full year estimated reported sales5 guidance at the midpoint by $2 billion dollars to 5.4% and full year EPS guidance by $0.25 to $10.85. Adjusted operational EPS increased to $10.68 at the midpoint.

Accepted abstracts include discussion of novel embolization approach to treating migraine and microcatheter retention risks for liquid embolic agents

New flow rate guidance designed to optimize irrigation and support consistent procedural outcomes 10,000+ VARIPULSE global procedures with low adverse event rate reinforces platform’s strong safety profile

Health workers and first responders bear a double burden as survivors themselves, dealing with their own losses while helping their communities recover and rebuild in the aftermath of a disaster.

Independent Director since 2013